Eloxx pharmaceuticals, inc. (ELOX)
Income statement / Yearly
Dec'19Dec'18Dec'17Jun'17Dec'16Jun'16Dec'15Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10
Operating expenses:
Research and development

25,842

20,489

16,398

280

8,986

2,182

5,842

4,568

3,338

2,086

2,566

3,720

2,637

Licensing Revenue

-

-

-

-

-

75

-

75

100

0

200

0

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

140

General and administrative

24,713

26,482

2,702

480

854

1,606

442

3,170

3,683

2,499

2,724

2,610

2,349

Reverse merger related expenses

-

594

1,290

-

-

-

-

-

-

-

-

-

-

Gain on sale of patents

-

-

-

149

-

0

-

0

-

-

-

-

-

Reverse merger related expenses

-

-

-

-

-

-

-

-

544

0

0

-

-

Total operating expenses

50,555

47,565

20,390

-

9,840

-

6,284

-

-

-

-

-

-

Impairment of patents

-

-

-

-

-

-

-

-

-

-

0

-

-

Impairment of goodwill

-

-

-

-

-

5,780

-

8,121

0

0

321

1,588

-

Impairment of acquired R&D

-

-

-

1,600

-

1,700

-

0

0

-

-

-

-

Impairment and write-off of patents

-

-

-

-

-

0

-

-2,290

-1,680

-64

-

-

-

Total operating expenses

-

-

-

2,210

-

11,269

-

18,151

9,247

4,650

5,611

7,918

4,986

Loss from operations

-50,555

-47,565

-20,390

-2,210

-9,840

-11,194

-6,284

-18,076

-9,147

-4,650

-5,411

-7,918

-4,846

Financial and other expenses

-

-

-

-

-

-

122

-

-

-

-

-

-

Change in fair value of stock right

-

-

-

428

-

254

-

12

0

0

-

-

-

Other expense (income), net

-319

502

-824

-

-7

-

-

-

-

-

-

-

-

Grant income

-

-

-

-

-

-

-

-

-

-

-

244

-

Change in fair value of warrant liability

-

-

-

208

-

1,993

-

3

0

371

472

609

-

Change in fair value of note derivative

-

-

-

0

-

-

-

-

-

-

-

-

-

Stock issuance for anti-dilution right

-

-

-

-

-

0

-

0

-

-

-

-

-

Fair value - warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

2,516

Sale of state income tax loss - net

-

-

-

-

-

-

-

-

-

-

-

0

-

Other noncash (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-115

-

Loss on settlement of warrant liabilities

-

-

-

-

-

-

-

-

-

-1,724

0

0

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

0

-361

Amortization of debt discount and financing costs

-

-

-

-

-

-

-

-

-

-

-

0

10,081

Interest expense - convertible notes

-

-

-

-

-

-

-

-

-

-

-

0

586

Interest expense

-

-

-

-0

-

-0

-

-2

-77

-119

-127

-88

-24

Loss before income taxes

-50,874

-47,063

-21,214

-1,573

-9,847

-8,947

-

-18,063

-9,225

-

-

-

-

Provision for income taxes

0

122

-

-640

-

-680

-

0

0

-

-

-

-

Net loss

-50,874

-47,185

-21,214

-933

-9,847

-8,267

-6,406

-18,063

-9,225

-6,122

-5,066

-7,268

-13,383

Less: dividends accumulated for the period

-

-

-2,404

-

-1,100

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-50,874

-47,185

-23,618

-

-10,947

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted

-1.34

-1.45

-4.75

-0.05

-2.60

-0.42

1.67

-1.31

-2.53

-5.11

-7.81

-0.14

-0.67

Weighted average number of shares of common stock used in computing net loss per share, basic and diluted

38,063

32,436

4,976

20,496

4,205

20,322

4,148

14,417

5,476

1,366

857

69,332

29,112

Comprehensive loss:
Net loss

-50,874

-47,185

-21,214

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-50,874

-47,185

-23,618

-

-

-

-

-

-

-

-

-

-

Other comprehensive income (loss):
Change in unrealized gain (loss) on available-for-sale securities

18

-

-

-

-

-

-

-

-

-

-

-

-

Preferred dividends

-

-

-

9

-

179

-

838

4,629

862

1,625

2,638

6,239

Net loss applicable to common shares

-

-

-

-943

-

-8,447

-

-18,902

-13,854

-6,985

-6,691

-9,907

-19,623

Other comprehensive loss

-

-

-

-

-

-

-

-

0

0

0

0

-

Comprehensive loss

-50,856

-47,185

-23,618

-

-

-

-

-

-13,854

-6,985

-6,691

-9,907

-